Oral and intravenous zidovudine pharmacokinetics: The effect of granulocyte-macrophage colony stimulating factor

F. T. Aweeka, M. Mak, Amira Al-Uzri, K. Peter, C. Dett, J. Franco, M. Affrime, R. Guerciolini, D. L. Cutler, J. Kahn, J. G. Gambertoglio

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Combination therapy with zidovudine and recombinant human granulocyte- macrophage colony stimulating factor (rHu GM-CSF) may be warranted, owing to the bone marrow suppressive effects of zidovudine. A study of 16 patients, 8 of whom had acquired immune deficiency syndrome (AIDS) and 8 of whom were infected with human immunodeficiency virus (HIV) but were asymptomatic, was conducted. The effect of 4 days of rHU GM-CSF versus placebo on intermittent zidovudine therapy (200 mg every 8 hours) was evaluated using a randomized, cross-over study design. Pharmacokinetics of oral and intravenous zidovudine were determined on days 1 (oral), 3 (oral), and 4 (intravenous) of rHu-GM- CSF (placebo) administration. After intravenous dosing, zidovudine plasma clearance for placebo and rHu GM-CSF averaged 1.4 ± 0.2 and 1.3 ± 0.2 L/hr/kg, respectively (P = 0.017), mean residence time averaged 1.5 ± 0.5 and 1.9 ± 0.6 hours, respectively (P = 0.012), and the steady-state volume of distribution was 2.0 ± 0.7 and 2.3 ± 0.7 L/kg, respectively (P = 0.027) for the two treatment arms. Stratified data .for patients with AIDS and those with asymptomatic HIV infection revealed no significant difference in plasma clearance or mean residence time between the two patient groups. These pharmacokinetic results indicate that dosage adjustments for zidovudine are not warranted when administered with rHu GM-CSF owing to the small changes observed. However, the statistically significant increase in Vss suggests the possibility of enhanced zidovudine cellular uptake in the presence of rHu GM- CSF.

Original languageEnglish (US)
Pages (from-to)856-864
Number of pages9
JournalJournal of Clinical Pharmacology
Volume35
Issue number9
StatePublished - 1995
Externally publishedYes

Fingerprint

Zidovudine
Granulocyte-Macrophage Colony-Stimulating Factor
Pharmacokinetics
Placebos
Cross-Over Studies
Acquired Immunodeficiency Syndrome
HIV
Virus Diseases
Therapeutics
Bone Marrow

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Aweeka, F. T., Mak, M., Al-Uzri, A., Peter, K., Dett, C., Franco, J., ... Gambertoglio, J. G. (1995). Oral and intravenous zidovudine pharmacokinetics: The effect of granulocyte-macrophage colony stimulating factor. Journal of Clinical Pharmacology, 35(9), 856-864.

Oral and intravenous zidovudine pharmacokinetics : The effect of granulocyte-macrophage colony stimulating factor. / Aweeka, F. T.; Mak, M.; Al-Uzri, Amira; Peter, K.; Dett, C.; Franco, J.; Affrime, M.; Guerciolini, R.; Cutler, D. L.; Kahn, J.; Gambertoglio, J. G.

In: Journal of Clinical Pharmacology, Vol. 35, No. 9, 1995, p. 856-864.

Research output: Contribution to journalArticle

Aweeka, FT, Mak, M, Al-Uzri, A, Peter, K, Dett, C, Franco, J, Affrime, M, Guerciolini, R, Cutler, DL, Kahn, J & Gambertoglio, JG 1995, 'Oral and intravenous zidovudine pharmacokinetics: The effect of granulocyte-macrophage colony stimulating factor', Journal of Clinical Pharmacology, vol. 35, no. 9, pp. 856-864.
Aweeka, F. T. ; Mak, M. ; Al-Uzri, Amira ; Peter, K. ; Dett, C. ; Franco, J. ; Affrime, M. ; Guerciolini, R. ; Cutler, D. L. ; Kahn, J. ; Gambertoglio, J. G. / Oral and intravenous zidovudine pharmacokinetics : The effect of granulocyte-macrophage colony stimulating factor. In: Journal of Clinical Pharmacology. 1995 ; Vol. 35, No. 9. pp. 856-864.
@article{38d8ded1ec28473ebb4ef848f136d0c0,
title = "Oral and intravenous zidovudine pharmacokinetics: The effect of granulocyte-macrophage colony stimulating factor",
abstract = "Combination therapy with zidovudine and recombinant human granulocyte- macrophage colony stimulating factor (rHu GM-CSF) may be warranted, owing to the bone marrow suppressive effects of zidovudine. A study of 16 patients, 8 of whom had acquired immune deficiency syndrome (AIDS) and 8 of whom were infected with human immunodeficiency virus (HIV) but were asymptomatic, was conducted. The effect of 4 days of rHU GM-CSF versus placebo on intermittent zidovudine therapy (200 mg every 8 hours) was evaluated using a randomized, cross-over study design. Pharmacokinetics of oral and intravenous zidovudine were determined on days 1 (oral), 3 (oral), and 4 (intravenous) of rHu-GM- CSF (placebo) administration. After intravenous dosing, zidovudine plasma clearance for placebo and rHu GM-CSF averaged 1.4 ± 0.2 and 1.3 ± 0.2 L/hr/kg, respectively (P = 0.017), mean residence time averaged 1.5 ± 0.5 and 1.9 ± 0.6 hours, respectively (P = 0.012), and the steady-state volume of distribution was 2.0 ± 0.7 and 2.3 ± 0.7 L/kg, respectively (P = 0.027) for the two treatment arms. Stratified data .for patients with AIDS and those with asymptomatic HIV infection revealed no significant difference in plasma clearance or mean residence time between the two patient groups. These pharmacokinetic results indicate that dosage adjustments for zidovudine are not warranted when administered with rHu GM-CSF owing to the small changes observed. However, the statistically significant increase in Vss suggests the possibility of enhanced zidovudine cellular uptake in the presence of rHu GM- CSF.",
author = "Aweeka, {F. T.} and M. Mak and Amira Al-Uzri and K. Peter and C. Dett and J. Franco and M. Affrime and R. Guerciolini and Cutler, {D. L.} and J. Kahn and Gambertoglio, {J. G.}",
year = "1995",
language = "English (US)",
volume = "35",
pages = "856--864",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Oral and intravenous zidovudine pharmacokinetics

T2 - The effect of granulocyte-macrophage colony stimulating factor

AU - Aweeka, F. T.

AU - Mak, M.

AU - Al-Uzri, Amira

AU - Peter, K.

AU - Dett, C.

AU - Franco, J.

AU - Affrime, M.

AU - Guerciolini, R.

AU - Cutler, D. L.

AU - Kahn, J.

AU - Gambertoglio, J. G.

PY - 1995

Y1 - 1995

N2 - Combination therapy with zidovudine and recombinant human granulocyte- macrophage colony stimulating factor (rHu GM-CSF) may be warranted, owing to the bone marrow suppressive effects of zidovudine. A study of 16 patients, 8 of whom had acquired immune deficiency syndrome (AIDS) and 8 of whom were infected with human immunodeficiency virus (HIV) but were asymptomatic, was conducted. The effect of 4 days of rHU GM-CSF versus placebo on intermittent zidovudine therapy (200 mg every 8 hours) was evaluated using a randomized, cross-over study design. Pharmacokinetics of oral and intravenous zidovudine were determined on days 1 (oral), 3 (oral), and 4 (intravenous) of rHu-GM- CSF (placebo) administration. After intravenous dosing, zidovudine plasma clearance for placebo and rHu GM-CSF averaged 1.4 ± 0.2 and 1.3 ± 0.2 L/hr/kg, respectively (P = 0.017), mean residence time averaged 1.5 ± 0.5 and 1.9 ± 0.6 hours, respectively (P = 0.012), and the steady-state volume of distribution was 2.0 ± 0.7 and 2.3 ± 0.7 L/kg, respectively (P = 0.027) for the two treatment arms. Stratified data .for patients with AIDS and those with asymptomatic HIV infection revealed no significant difference in plasma clearance or mean residence time between the two patient groups. These pharmacokinetic results indicate that dosage adjustments for zidovudine are not warranted when administered with rHu GM-CSF owing to the small changes observed. However, the statistically significant increase in Vss suggests the possibility of enhanced zidovudine cellular uptake in the presence of rHu GM- CSF.

AB - Combination therapy with zidovudine and recombinant human granulocyte- macrophage colony stimulating factor (rHu GM-CSF) may be warranted, owing to the bone marrow suppressive effects of zidovudine. A study of 16 patients, 8 of whom had acquired immune deficiency syndrome (AIDS) and 8 of whom were infected with human immunodeficiency virus (HIV) but were asymptomatic, was conducted. The effect of 4 days of rHU GM-CSF versus placebo on intermittent zidovudine therapy (200 mg every 8 hours) was evaluated using a randomized, cross-over study design. Pharmacokinetics of oral and intravenous zidovudine were determined on days 1 (oral), 3 (oral), and 4 (intravenous) of rHu-GM- CSF (placebo) administration. After intravenous dosing, zidovudine plasma clearance for placebo and rHu GM-CSF averaged 1.4 ± 0.2 and 1.3 ± 0.2 L/hr/kg, respectively (P = 0.017), mean residence time averaged 1.5 ± 0.5 and 1.9 ± 0.6 hours, respectively (P = 0.012), and the steady-state volume of distribution was 2.0 ± 0.7 and 2.3 ± 0.7 L/kg, respectively (P = 0.027) for the two treatment arms. Stratified data .for patients with AIDS and those with asymptomatic HIV infection revealed no significant difference in plasma clearance or mean residence time between the two patient groups. These pharmacokinetic results indicate that dosage adjustments for zidovudine are not warranted when administered with rHu GM-CSF owing to the small changes observed. However, the statistically significant increase in Vss suggests the possibility of enhanced zidovudine cellular uptake in the presence of rHu GM- CSF.

UR - http://www.scopus.com/inward/record.url?scp=0029113165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029113165&partnerID=8YFLogxK

M3 - Article

C2 - 8786245

AN - SCOPUS:0029113165

VL - 35

SP - 856

EP - 864

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 9

ER -